

Alert	<p>Watch for apnoeas and abdominal distension following administration. Lower concentration solutions and regimens minimising number of additional drops are recommended.</p> <p>ANMF group reviewed the recent manufacturer's advice contraindicating its use in preterm infants and children with Down's Syndrome, based on a few case reports for adverse events. In consultation with specialist ophthalmologists, ANMF group has recommended its continued use for ROP screening, where strategies are in place to reduce the risk of systemic side effects (e.g. increased monitoring in preterm infants).</p>
Indication	<p>Eye examination</p> <p>Retinopathy of prematurity (ROP) Screening</p> <p>Post-operative care following ROP photocoagulation/anti-VEGF therapy.</p>
Action	Muscarinic acetylcholine receptor competitive antagonist. Mydriatic (dilates the pupil) and cycloplegic (prevents accommodation of the eye) for ophthalmic examinations and therapeutic procedures.
Drug type	Antimuscarinic.
Trade name	Minims® Cyclopentolate hydrochloride.
Presentation	Cyclopentolate hydrochloride 0.5% single-use preservative free eye drop, 0.5 mL per minim.
Dose	<p>Eye examination/ROP screening</p> <p>Cyclopentolate 0.5% is used in combination with phenylephrine 2.5% with or without tropicamide 0.5%. Suggested regimens are:</p> <p>REGIMEN 1:</p> <p>Phenylephrine 2.5% + cyclopentolate 0.5% + tropicamide 0.5% eye drops [1-4].</p> <p>REGIMEN 2:</p> <p>Phenylephrine 2.5% + cyclopentolate 0.5% eye drops [5].</p> <p>Dark irides may require additional drops.</p> <p>Post ROP photocoagulation/anti-VEGF therapy*</p> <p>*Dose, frequency and duration may vary based on infant's status on ROP, pupil and iris.</p> <p>Suggested dose: 1-2 drops in the affected eye BD.</p>
Dose adjustment	<p>Therapeutic hypothermia – No information.</p> <p>ECMO – No information.</p> <p>Renal impairment – No information.</p> <p>Hepatic impairment – No information.</p>
Maximum dose	<p>REGIMEN 1: 3 drops of each eye drop.</p> <p>REGIMEN 2: 4 drops of each eye drop.</p>
Total cumulative dose	
Route	Topical instillation into the eyes from the minim.
Preparation	Not applicable.
Administration	<p>Regimen 1</p> <p>Instil one drop of each agent (5 minutes apart) into each eye 60 minutes prior to examination. Repeat if pupillary dilatation inadequate. Perform examination 60 to 120 minutes after instillation.</p> <p>Regimen 2</p> <p>Instil one drop of each agent (5 minutes apart) into each eye 60 minutes prior to examination. Repeat if pupillary dilatation inadequate. Perform examination 60 to 120 minutes after instillation. Apply pressure to the lacrimal sac during and for 60 seconds after instillation of eye drop to minimise systemic absorption. Wipe away excess medication. Consider withholding feeds for four hours from administration of the last drops to reduce incidence of feed intolerance.</p>
Monitoring	<p>Heart rate and oxygen saturation in infants with bronchopulmonary dysplasia.</p> <p>Signs of ileus.</p>

Contraindications	Hypersensitivity to components of the preparation, necrotising enterocolitis (NEC) at the time of eye examination. Untreated narrow angle glaucoma [6].
Precautions	Bronchopulmonary dysplasia – may increase absorption, decrease clearance [7]. Infants on oxygen may have comparatively higher serum concentrations. Severe neurological impairment – may increase risk of seizures and anticholinergic syndrome. Infants with feeding intolerance, Shallow anterior chamber of eye and Downs Syndrome [6-9]. Lower concentration solutions and regimens minimising number of additional drops are recommended to minimise toxicity.
Drug interactions	Potential of anticholinergic effects of Amantadine, Clozapine, Glycopyrrolate, Quetiapine, Revefenacin, Scopolamine, Tiotropium Increased risk of seizures when used with Bupropion, Donepezil Loss of efficacy of Cisapride, Methacholine Increased gastro-intestinal side effects of Glucagon, Potassium Citrate.
Adverse reactions	Stinging or burning of eye, peri-ocular erythema or pallor Feeding intolerance, abdominal distension and increased gastric residuals. Apnoea and desaturations. Transient bradycardia (especially infants on respiratory support), tachycardia, arrhythmia and increase or drop in blood pressure. Rarely, dry mouth, urinary retention, fever, vasodilatation, restlessness, agitation, hypotonia, reduced consciousness, seizures, necrotising enterocolitis and cardiopulmonary arrest. Increase in intraocular pressure and precipitation of acute angle-closure glaucoma in predisposed infants [6-10]
Compatibility	Phenylephrine, tropicamide, amethocaine
Incompatibility	No information.
Stability	Discard unused portion immediately after use.
Storage	Store at 2°C to 8°C. (Refrigerate. Do not freeze.) Protect from light. Each Minims unit should be discarded after a single use.
Excipients	Purified water, hydrochloric acid
Special comments	Check correct strength of Minims® Cyclopentolate Eye Drops. Do NOT use 1% in neonates. Microdrop administration could be safer but needs further investigation and validation [11, 12].
Evidence	<p>Efficacy</p> <p>Cyclopentolate alone (muscarinic acetylcholine antagonist): Several controlled trials have compared cyclopentolate 0.5% to 1% versus other individual eye drops (phenylephrine [α1-adrenoceptor agonist] or tropicamide [muscarinic acetylcholine antagonist]) or combination eye drops.</p> <p>Caputo et al, in a controlled study of 40 preterm infants, reported phenylephrine 1.0% or 2.5% or cyclopentolate 1% or tropicamide 1% (3 drops) produced inadequate mydriasis for peripheral retinal examination. A combination of phenylephrine 2.5% + cyclopentolate 0.5% + tropicamide 0.5% 1 to 3 drops of each produced adequate mydriasis (average 7.0 mm). Cyclopentolate 1% increased heart rate and BP.[4]</p> <p>Isenberg et al, in a controlled study of 30 preterm infants, reported phenylephrine 1% + cyclopentolate 0.2% (2 drops) combination produced greater mydriasis than cyclopentolate 0.5% + tropicamide 0.5% (2 drops), or cyclopentolate 0.5% (2 drops) alone. There was no blood pressure increase with cyclopentolate 0.5% (2 drops) [13].</p> <p>Ogut et al, in a parallel RCT in 80 preterm infants, reported cyclopentolate 1% (2 drops) produced net pupillary dilatation 3.8 mm. Maximum mydriasis was achieved with cyclopentolate 0.5% + tropicamide 0.5% + 2.5% phenylephrine (1 drop). Adequate mydriasis without side effects was achieved with 1% cyclopentolate + 1% tropicamide (1 drop).[2]</p> <p>Conclusion: Cyclopentolate 0.5% alone does not achieve optimal mydriasis. Cyclopentolate 1% may be associated with physiological side effects. Combination eye drops produce greater mydriasis and/or fewer physiological side effects than cyclopentolate alone. [LOE II GOR B] Phenylephrine 2.5% + cyclopentolate combination may be more effective than tropicamide 0.5% + cyclopentolate combination. [LOE II GOR C]</p> <p>Cyclopentolate combination (excluding Cyclomydril [cyclopentolate 0.2% + phenylephrine 1%]): Several trials have assessed the efficacy and safety of cyclopentolate 0.5% to 1% in combination with phenylephrine [α1-adrenoceptor agonist] and/or tropicamide [muscarinic acetylcholine antagonist].</p>

Chew et al, in a parallel RCT in 39 preterm infants, reported cyclopentolate 0.2% + phenylephrine 1% 3 drops provided adequate pupillary dilation with the least systemic side effects; combination cyclopentolate 1% + phenylephrine 2.5% and tropicamide 1% + phenylephrine 2.5% were associated with increased BP; and cyclopentolate 1% + phenylephrine 2.5% may be associated with feed intolerance [14]. Bolt et al, in a parallel RCT in 39 preterm infants, reported the mydriatic effect of the phenylephrine 2.5% + tropicamide 0.5% combination was significantly superior to that of the cyclopentolate 0.5% + tropicamide 0.5% combination. A significant increase in BP and HR peak values was observed within 7 to 10 minutes after the cyclopentolate 0.5% + tropicamide 0.5% combination only [15].

Sindel et al, in a parallel RCT in 34 preterm infants, reported mydriasis with phenylephrine 1.0% + tropicamide 1.0% was significantly less than phenylephrine 2.5% + tropicamide 1.0% or phenylephrine 2.5% + tropicamide 0.5% + cyclopentolate 0.5%. Dilatation was sufficient to allow appropriate examination in all infants (pupillary diameter > 6.0 mm). BP and heart rate increased transiently in all groups receiving mydriatic but returned to baseline values in 25 minutes. This increase was significant with 2.5% phenylephrine.[3]

Ogut et al, in a parallel RCT in 80 preterm infants, reported maximum mydriasis was achieved with cyclopentolate 0.5% + tropicamide 0.5% + 2.5% phenylephrine (1 drop each); and adequate mydriasis without side effects was achieved with 1% cyclopentolate + 1% tropicamide (1 drop each).[2]

Merritt et al, in a crossover RCT in 30 preterm infants, compared phenylephrine 2.5% + tropicamide 0.5% + cyclopentolate 0.5% (1 drop each) to saline control and reported maximal mydriasis at 75–90 minutes with adequate funduscopy at 120 minutes, and no significant effect on systolic BP.[1]

Nefendorf et al, in a cohort of 1246 eyes screened during 623 examinations of 138 infants, reported phenylephrine 2.5% + cyclopentolate 0.5% eye drops (3 times 5 minutes apart) was efficacious with 98.8% successful dilatation and well-tolerated although 0.8% had significant clinical deterioration in the following 24 hours.[5]

Wheatcroft et al, in a controlled study comparing effects in each eye in 26 preterm infants, reported no difference in mydriasis from 5 microL versus 26 microL drops of cyclopentolate 0.5% and phenylephrine 2.5% (mean pupil diameter 6.05 mm [range 4.5 to 7.1 mm]) in the eyes dilated with standard drops and 6.1 mm [range 5.0 -7.5 mm] in microdrop eyes) [16].

Conclusion: Cyclopentolate 0.5% + phenylephrine 2.5% combination produces adequate mydriasis [5] but may have physiological side effects and was associated with clinical deterioration in the following 24 hours in 0.8% of infants examined.[5] (LOE II GOR C) Cyclopentolate 0.5% + tropicamide 0.5% may not produce adequate mydriasis [15]. [LOE II GOR C] Adequate mydriasis without side effects was achieved with 1% cyclopentolate + 1% tropicamide.[2] [LOE II GOR C]

Safety

Cyclopentolate alone (muscarinic acetylcholine antagonist): Clinical studies have reported variable physiological effects from use of cyclopentolate. Caputo et al [4] reported cyclopentolate 1% increased heart rate and BP whereas Isenberg et al reported no blood pressure increase with cyclopentolate 0.5% (2 drops) [13]. Nefendorf et al, in a cohort of 1246 eyes screened during 623 examinations of 138 infants, reported phenylephrine 2.5% + cyclopentolate 0.5% eye drops (3 times 5 minutes apart) was efficacious with 98.8% successful dilatation and well-tolerated [5]. There were no systemic adverse reactions necessitating abandonment of the examination. However, 0.8% had significant clinical deterioration in the 24 hours after examination.

Potential side effects reported in case series and case reports include: feeding intolerance (abdominal distension and increased gastric aspirates) within 24 hours of mydriatic administration including cyclopentolate [17, 18]; acute gastric dilatation with the use of cyclopentolate 0.5% and phenylephrine 2.5% [19]; necrotising enterocolitis following the use of cyclopentolate eye drops [20, 21, 22]; seizures [23, 24, 25] and cardiac arrest [26]. However, causation has not been proven. In an observational study, feeding intolerance was reported to be reduced after introducing a 4-hour fasting period after instillation of eye drops [17].

Conclusions: Cyclopentolate 1% produces greater physiological effects than cyclopentolate 0.5%. Three drop regimens of combination eye drops were associated with more acute physiological effects and feed intolerance [14, 27]. [LOE II GOR B]

Pharmacokinetics and pharmacodynamics

Merritt et al reported maximal mydriasis at 75–90 minutes with adequate funduscopy at 120 minutes using phenylephrine 2.5% + tropicamide 0.5% + cyclopentolate 0.5% 1 drop each.[1]

	<p>Approximately 80% of each drop may pass through the nasolacrimal system and be available for rapid systemic absorption by nasal mucosa without lacrimal sac occlusion [28]. Finger pressure on the lacrimal punctum at the medial canthus of the eye immediately after installation of eye drops for at least 60 seconds reduces systemic absorption [28].</p> <p>Mitchell et al reported cyclopentolate and phenylephrine serum concentrations in 18 preterm infants one hour after instillation of cyclopentolate 0.2% and phenylephrine 1% one drop each eye every five minutes for a total of three doses. Cyclopentolate (range 6–53 ng/ml) was observed in 15 of 18 infants, while phenylephrine was not detected. Concentrations of cyclopentolate were significantly higher in infants who were on oxygen. There was a significant association between cyclopentolate concentrations and gastric residuals in tube-fed infants not receiving oxygen [7].</p>
Practice points	
References	<ol style="list-style-type: none"> 1. Merritt JC, Kraybill EN. Effect of mydriatics on blood pressure in premature infants. <i>Journal of Pediatric Ophthalmology and Strabismus</i>. 1981;18:42-6. 2. Ogut MS, Bozkurt N, Ozek E, Birgen H, Kazokoglu H, Ogut M. Effects and side effects of mydriatic eyedrops in neonates. <i>European Journal of Ophthalmology</i>. 1996;6:192-6. 3. Sindel BD, Baker MD, Maisels MJ, Weinstein J. A comparison of the pupillary and cardiovascular effects of various mydriatic agents in preterm infants. <i>Journal of Pediatric Ophthalmology and Strabismus</i>. 1986;23:273-6. 4. Caputo A, Schnitzer R. Systemic response to mydriatic eyedrops in neonates: Mydriatics in neonates. <i>Journal of Pediatric Ophthalmology and Strabismus</i>. 1978;15:109-22. 5. Nefendorf JE, Michael Mota P, Xue K, Darius Hildebrand G. Efficacy and safety of phenylephrine 2.5% with cyclopentolate 0.5% for retinopathy of prematurity screening in 1246 eye examinations. <i>European Journal of Ophthalmology</i>. 2015;25:249-53. 6. MIMS update 20121. https://mailchi.mp/c2e4d1cd544b/xj1kyu1cp8-703007?e=4708998865. 7. Mitchell A, Hall RW, Erickson SW, Yates C, Hendrickson H. Systemic Absorption of Cyclopentolate and Adverse Events After Retinopathy of Prematurity Exams. <i>Current Eye Research</i>. 2016;41:1601-7. 8. Mir GH, Cumming GR. Response to atropine in Down's syndrome. <i>Arch Dis Child</i>. 1971 Feb;46(245):61-5. 9. Parsa CF, Adyanthaya R. Why atropine drops should be used in Down syndrome. <i>Br J Ophthalmol</i>. 2008 Feb;92(2):295-6. 10. Kremer LJ, Reith DM, Medlicott N, Broadbent R. Systematic review of mydriatics used for screening of retinopathy in premature infants. <i>BMJ Paediatr Open</i>. 2019 May 9;3(1):e000448. 11. Kremer LJ, Broadbent R, Medlicott N, Sime MJ, McCaffrey F, Reith DM. Randomised controlled pilot trial comparing low dose and very low- dose microdrop administration of phenylephrine and cyclopentolate for retinopathy of prematurity eye examinations in neonates. <i>Arch Dis Child</i>. 2021 Jun;106(6):603-608. 12. Seliniotaki AK, Lithoxopoulou M, Talimtzis P, Georgiou E, Diamanti E, Ziakas N, Haidich AB, Mataftsi A. Efficacy and safety of mydriatic microdrops for retinopathy of prematurity screening: an external pilot crossover randomized controlled trial. <i>J Perinatol</i>. 2022 Mar;42(3):371-377. 13. Isenberg S, Everett S, Parelhoff E. A comparison of mydriatic eyedrops in low-weight infants. <i>Ophthalmology</i>. 1984;91:278-9. 14. Chew C, Rahman RA, Shafie SM, Mohamad Z. Comparison of mydriatic regimens used in screening for retinopathy of prematurity in preterm infants with dark irides. <i>Journal of Pediatric Ophthalmology and Strabismus</i>. 2005;42:166-73. 15. Bolt B, Benz B, Koerner F, Bossi E. A mydriatic eye-drop combination without systemic effects for premature infants: A prospective double-blind study. <i>Journal of Pediatric Ophthalmology and Strabismus</i>. 1992;29:157-62. 16. Wheatcroft S, Sharma A, McAllister J. Reduction in mydriatic drop size in premature infants. <i>Br J Ophthalmol</i>. 1993;77:364-5. 17. Hermansen MC, Hasan S. Abolition of feeding intolerance following ophthalmologic examination of neonates. <i>J Pediatr Ophthalmol Strabismus</i>. 1985;22:256-7. 18. Bonthala S, Sparks JW, Musgrove KH, Berseth CL. Mydriatics slow gastric emptying in preterm infants. <i>Journal of Pediatrics</i>. 2000;137:327-30.

	<p>19. Sarici SU, Yurdakok M, Unal S. Acute gastric dilatation complicating the use of mydriatics in a preterm newborn. <i>Pediatric Radiology</i>. 2001;31:581-3.</p> <p>20. Nair AK, Pai MG, Da Costa DE, Al Khusaiby SM. Necrotising enterocolitis following ophthalmological examination in preterm neonates. <i>Indian Pediatrics</i>. 2000;37:417-21.</p> <p>21. Ozgun U, Demet T, Ozge KA, Zafer D, Murat S, Mehmet Y, Nilgun K. Fatal necrotising enterocolitis due to mydriatic eye drops. <i>Journal of the College of Physicians and Surgeons Pakistan</i>. 2014;24:S147-S9.</p> <p>22. Siu LY, Chan WH, Au SK, Kwong NS. Necrotising enterocolitis following the use of mydriatics: A case report of two triplets. <i>Hong Kong Journal of Paediatrics</i>. 2011;16:47-50.</p> <p>23. Buyukcam A, Tolga Celik H, Korkmaz A, Yurdakok M. Myoclonic seizure due to cyclopentolate eye drop in a preterm infant. <i>Turkish Journal of Pediatrics</i>. 2012;54:419-20.</p> <p>24. Demayo AP, Reidenberg MM. Grand mal seizure in a child 30 minutes after Cyclogyl (cyclopentolate hydrochloride) and 10% Neo-Synephrine (phenylephrine hydrochloride) eye drops were instilled. <i>Pediatrics</i>. 2004;113:e499-500.</p> <p>25. Hu L, Dow K. Focal seizures after instillation of cyclomydril to a neonate with congenital CMV infection. <i>Journal of Neonatal-Perinatal Medicine</i>. 2014;7:147-9.</p> <p>26. Blohm E, Lai JT. Pediatric cardiac arrest after Cyclomydril(R) eye drops. <i>Clin-Toxicol-(Phila)</i> 2017;55No. 5</p> <p>27. Khoo BK, Koh A, Cheong P, Ho NK. Combination cyclopentolate and phenylephrine for mydriasis in premature infants with heavily pigmented irides. <i>Journal of Pediatric Ophthalmology and Strabismus</i>. 2000;37:15-20.</p> <p>28. Gray C. Systemic toxicity with topical ophthalmic medications in children. <i>Paediatric and Perinatal Drug Therapy</i>. 2006;7:23-9.</p>
--	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

VERSION/NUMBER	DATE
Original	16/02/2018
Current 2.0	28/04/2022
REVIEW	28/04/2027

Authors Contribution

Original author/s	Michael Hewson, Cathy Langdon
Current author	Nilkant Phad
Evidence Review	David Osborn
Expert review	Mark Jacobs, Hughie Tsang, Kimberley Tan
Nursing Review	Eszter Jozsa, Sarah Neale, Priya Govindaswamy
Pharmacy Review	Jing Xiao, Mariella De Rosa, Cindy Chen
ANMF Group contributors	Srinivas Bolisetty, Bhavesh Mehta, John Sinn, Ian Callander, Cindy Chen, Mohammad Irfan Azeem, Thao Tran, Michelle Jenkins, Helen Huynh, Simarjit Kaur
Final editing and review of the original	Ian Whyte
Electronic version	Mariella De Rosa, Cindy Chen, Ian Callander
Facilitator	Srinivas Bolisetty